Name | Platform | Indicated ages | Dose | WITHOUT moderate to severe immunocompromising condition | WITH moderate to severe immunocompromising condition | Common side effects |
Moderna COVID-19 vaccine (2023-2024 Formula) | mRNA | 6 months through 4 years | 25 mcg (0.25 mL dark blue-capped vial) | For individuals not previously vaccinated with any COVID-19 vaccine*:
| For individuals not previously vaccinated with any COVID-19 vaccine*:
|
|
5 through 11 years | 25 mcg dose (0.25 mL dark blue-capped vial) | For all immunocompetent individuals in these age groups:
| ||||
12 through 64 years | 50 mcg (0.5 mL) | |||||
65 years and older | 50 mcg (0.5 mL) | For all immunocompetent individuals in these age groups:
| ||||
Pfizer/BioNTech COVID-19 vaccine (2023-2024 Formula) | mRNA | 6 months through 4 yearsΔ | 3 mcg (0.3 mL yellow-capped vial) | For individuals not previously vaccinated with any COVID-19 vaccine*:
| For individuals not previously vaccinated with any COVID-19 vaccine*:
|
|
5 through 11 years | 10 mcg (0.3 mL blue-capped vial) | For all immunocompetent individuals in these age groups:
| For individuals not previously vaccinated with any COVID-19 vaccine*:
| |||
12 through 64 years | 30 mcg (0.3 mL) | |||||
65 years and older | 30 mcg (0.3 mL) | For all immunocompetent individuals in these age groups:
| ||||
Novavax COVID-19 vaccine (2023-2024 Formula) | Recombinant protein, adjuvanted | 12 through 64 years | 5 mcg spike protein/50 mcg adjuvant doses (0.5 mL) | For individuals not previously vaccinated with any COVID-19 vaccine:
For individuals who have received at least one prior COVID-19 vaccine dose (but not an updated 2023-2024 formula):
|
| |
65 years and older | 5 mcg spike protein/50 mcg adjuvant doses (0.5 mL) | For individuals not previously vaccinated with any COVID-19 vaccine:
For individuals who have received at least one prior COVID-19 vaccine dose (but not an updated 2023-2024 formula):
|
CDC: Centers for Disease Control and Prevention; COVID-19: coronavirus disease 2019.
* For individuals younger than five years of age and individuals with moderately to severely immunocompromising conditions who have already received previous vaccine doses, recommendations on updated vaccine doses depend on the number of prior vaccines received. If they have received at least three mRNA vaccine doses, the updated vaccine should be given at least eight weeks after the most recent dose. Refer to other UpToDate content for details.
¶ Although the FDA authorized intervals for the second doses of the Moderna, Novavax, and Pfizer COVID-19 bivalent vaccines are four, three, and three weeks after the first dose, respectively, the CDC suggests an interval up to eight weeks. Extending the interval to eight weeks between vaccine doses may be preferable for those (especially males aged 12 to 39 years) who have no major comorbidities and do not need to maximize protection within a shorter period of time; longer intervals may be associated with a lower risk of myocarditis and slightly improved effectiveness.[5]
Δ Children who turn five years of age during the series should receive all three doses with the formulation and dose recommended for children six months through four years.Do you want to add Medilib to your home screen?